$XON Intrexon Corp Climbing Up The Charts
XON has been making a nice run up the charts lately. We don't think this run is over by far as there looks to be a lot of momentum behind XON.
There's also a gap higher that needs to be closed from $12.77 to $12.96
The stock is getting a boost today after announcing an exclusive wellness agreement with Surterra Wellness.
The companies will join forces to advance Surterra's cannabinoid production at a reliable, efficient, cost-effective, industrial scale utilizing Intrexon's proprietary yeast fermentation platform. The $100 million deal, including milestones and royalties, will leverage each company's expertise to ultimately bring new cannabis products to market to meet growing, and more selective, future consumer demand, with greater supply chain security, in a more consistent, efficient and cost effective way.
As always, trade with caution and use protective stops.
Good luck to all!
There's also a gap higher that needs to be closed from $12.77 to $12.96
The stock is getting a boost today after announcing an exclusive wellness agreement with Surterra Wellness.
The companies will join forces to advance Surterra's cannabinoid production at a reliable, efficient, cost-effective, industrial scale utilizing Intrexon's proprietary yeast fermentation platform. The $100 million deal, including milestones and royalties, will leverage each company's expertise to ultimately bring new cannabis products to market to meet growing, and more selective, future consumer demand, with greater supply chain security, in a more consistent, efficient and cost effective way.
As always, trade with caution and use protective stops.
Good luck to all!
To receive our alerts via email and SMS, join Insider Financial for Free at signup.insiderfinancial.com
We are not financial advisors. Always conduct your own research and read our full disclaimer at insiderfinancial.com/disclaimer/
We are not financial advisors. Always conduct your own research and read our full disclaimer at insiderfinancial.com/disclaimer/
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.